{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:11:07Z","timestamp":1791882667192,"version":"4.3.4"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Integrase strand transfer inhibitor (INSTI) dolutegravir (DTG)-based antiretroviral therapy (ART) is recommended by World Health Organisation as preferred first-line regimen in pregnant women living with human immunodeficiency virus (HIV) (WLHIV). Non-nucleoside reverse transfer inhibitor (NNRTI)-based ART and protease inhibitor (PI)-based ART are designated as alternative regimens. The impact of different ART regimens on perinatal outcomes is uncertain. We aimed to assess the comparative risk of adverse perinatal outcomes in WLHIV receiving different classes of ART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A systematic literature review was conducted by searching PubMed, CINAHL, Global Health, and EMBASE for studies published between Jan 1, 1980, and July 14, 2023. We included studies reporting on the association of pregnant WLHIV receiving different classes of ART with 11 perinatal outcomes: preterm birth (PTB), very PTB, spontaneous PTB, low birthweight (LBW), very LBW, term LBW, preterm LBW, small for gestational age (SGA), very SGA (VSGA), stillbirth, and neonatal death. Pairwise random-effects meta-analyses compared the risk of each adverse perinatal outcome among WLHIV receiving INSTI-ART, NNRTI-ART, PI-ART, and nucleoside reverse transfer inhibitor (NRTI)-based ART, and compared specific \u201cthird drugs\u201d from different ART classes. Subgroup and sensitivity analyses were conducted based on country income status and study quality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty cohort studies published in 2006\u20132022, including 222,312 pregnant women, met the eligibility criteria. Random-effects meta-analyses found no evidence that INSTI-ART is associated with adverse perinatal outcomes compared to NNRTI-ART and PI-ART. We found that PI-ART is associated with a significantly increased risk of SGA (RR 1.28, 95% confidence interval (95% CI) [1.09, 1.51], <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and VSGA (RR 1.41, 95% CI [1.08, 1.83], <jats:italic>p<\/jats:italic>\u2009=\u20090.011), compared to NNRTI-ART. Specifically, lopinavir\/ritonavir (LPV\/r) was associated with an increased risk of SGA (RR 1.40, 95% CI [1.18, 1.65], <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and VSGA (RR 1.84, 95% CI [1.37, 2.45], <jats:italic>p<\/jats:italic>\u2009=\u20090.002), compared to efavirenz, but not compared to nevirapine. We found no evidence that any class of ART or specific \u201cthird drug\u201d was associated with an increased risk of PTB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings support the recommendation of INSTI-ART as first-line ART regimen for use in pregnant WLHIV. However, the increased risks of SGA and VGSA associated with PI-ART, compared to NNRTI-ART, may impact choice of second- and third-line ART regimens in pregnancy.<\/jats:p><jats:p><jats:bold>Systematic review registration<\/jats:bold>: <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42021248987.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1323813","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T04:50:56Z","timestamp":1709009456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparative risk of adverse perinatal outcomes associated with classes of antiretroviral therapy in pregnant women living with HIV: systematic review and meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Katharina","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Cowdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Portwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kumarendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Kirtley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Hemelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"ref1","volume-title":"Global AIDS update. Geneva: UNAIDS","year":"2023"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2214-109X(21)00515-5","article-title":"Global, regional, and national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by the UN inter-agency Group for Child Mortality Estimation","volume":"10","author":"Sharrow","year":"2022","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2352-4642(21)00311-4","article-title":"Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the sustainable development goals","volume":"6","author":"Perin","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"j3677","DOI":"10.1136\/bmj.j3677","article-title":"Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21st standard: analysis of CHERG datasets","volume":"358","author":"Lee","year":"2017","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S2214-109X(13)70006-8","article-title":"National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Glob Health"},{"key":"ref6","volume-title":"Transforming our world: The 2030 agenda for sustainable development","year":"2015"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(15)00207-6","article-title":"Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis","volume":"3","author":"Wedi","year":"2016","journal-title":"Lancet HIV"},{"key":"ref8","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","year":"2013"},{"key":"ref9","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","year":"2016"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s43856-023-00331-8","article-title":"Adverse perinatal outcomes attributable to HIV in sub-Saharan Africa from 1990 to 2020: systematic review and meta-analyses","volume":"3","author":"Murray","year":"2023","journal-title":"Commun Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/QAD.0000000000003248","article-title":"Adverse perinatal outcomes associated with HAART and monotherapy","volume":"36","author":"Portwood","year":"2022","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/infdis\/jiv390","article-title":"Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room?","volume":"213","author":"Mofenson","year":"2016","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/S2352-3018(18)30059-6","article-title":"HIV treatment in pregnancy","volume":"5","author":"Bailey","year":"2018","journal-title":"Lancet HIV"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1056\/NEJMoa0907736","article-title":"Antiretroviral regimens in pregnancy and breast-feeding in Botswana","volume":"362","author":"Shapiro","year":"2010","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/hiv.12083","article-title":"Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission","volume":"15","author":"Short","year":"2014","journal-title":"HIV Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/QAD.0000000000001694","article-title":"Protease inhibitors and preterm delivery: another piece in the puzzle","volume":"32","author":"Favarato","year":"2018","journal-title":"AIDS"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/QAD.0000000000002039","article-title":"Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes","volume":"33","author":"Bailey","year":"2019","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/infdis\/jis553","article-title":"Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana","volume":"206","author":"Chen","year":"2012","journal-title":"J Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/QAD.0b013e328133884b","article-title":"Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland","volume":"21","author":"Townsend","year":"2007","journal-title":"AIDS"},{"key":"ref20","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization","year":"2021"},{"key":"ref21","volume-title":"Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services","year":"2024"},{"key":"ref22","volume-title":"Treatment of pregnant women living with HIV or women considering pregnancy","year":"2022"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/QAD.0000000000002593","article-title":"Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis","volume":"34","author":"Tshivuila-Matala","year":"2020","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/infdis\/jir307","article-title":"Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy","volume":"204","author":"Powis","year":"2011","journal-title":"J Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","article-title":"Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial","volume":"7","author":"Kintu","year":"2020","journal-title":"Lancet HIV"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","article-title":"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010\/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S2352-3018(20)30038-2","article-title":"Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial","volume":"7","author":"Jo\u00e3o","year":"2020","journal-title":"Lancet HIV"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2214-109X(18)30451-0","article-title":"Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis","volume":"7","author":"Chawanpaiboon","year":"2019","journal-title":"Lancet Glob Health"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1016\/S2214-109X(18)30565-5","article-title":"National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis","volume":"7","author":"Blencowe","year":"2019","journal-title":"Lancet Glob Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(16)31575-6","article-title":"Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/135030","article-title":"Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy","volume":"2012","author":"Aaron","year":"2012","journal-title":"Infect Dis Obstet Gynecol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/QAD.0000000000002464","article-title":"Investigation of factors associated with spontaneous preterm birth in pregnant women living with HIV","volume":"34","author":"Albert","year":"2020","journal-title":"AIDS"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e01068","DOI":"10.1128\/AAC.01068-20","article-title":"Efficacy of three antiretroviral regimens initiated during pregnancy: clinical experience in Rio de Janeiro","volume":"64","author":"Benamor Teixeira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/picr.PICR_74_19","article-title":"Treatment outcome of different antiretroviral drug regimens in HIV-positive pregnant women","volume":"12","author":"Chauhan","year":"2021","journal-title":"Perspect Clin Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12978-018-0513-8","article-title":"Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study","volume":"15","author":"Delicio","year":"2018","journal-title":"Reprod Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e027344","DOI":"10.1136\/bmjopen-2018-027344","article-title":"Pregnancy outcome among HIV-infected women on different antiretroviral therapies in Ethiopia: a cohort study","volume":"9","author":"Ejigu","year":"2019","journal-title":"BMJ Open"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2393-12-93","article-title":"Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women","volume":"12","author":"Ezechi","year":"2012","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QAI.0000000000002087","article-title":"Stillbirth in women living with HIV delivering in the United Kingdom and Ireland: 2007-2015","volume":"82","author":"Favarato","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s15010-019-01384-5","article-title":"Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study","volume":"48","author":"Floridia","year":"2020","journal-title":"Infection"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/QAI.0000000000002882","article-title":"Impact of integrase Strand transfer inhibitor use during pregnancy on viral suppression at delivery and infant outcomes: a statewide retrospective cohort study","volume":"89","author":"Latham","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10096-014-2224-6","article-title":"Risk of intrauterine growth restriction among HIV-infected pregnant women: a cohort study","volume":"34","author":"L\u00f3pez","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/sti.2008.032300","article-title":"Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception","volume":"85","author":"Machado","year":"2009","journal-title":"Sex Transm Infect"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa2200600","article-title":"Dolutegravir in pregnancy as compared with current HIV regimens in the United States","volume":"387","author":"Patel","year":"2022","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/INF.0000000000002984","article-title":"Preterm birth and antiretroviral exposure in infants HIV-exposed uninfected","volume":"40","author":"Piske","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"ref47","first-page":"359s","article-title":"Comparisonof four classical PI- and raltegravir-based regimens during pregnancy","author":"Sibiude","year":"2018","journal-title":"Top. Antiv. Med."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/QAD.0000000000002719","article-title":"Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy","volume":"35","author":"Sibiude","year":"2021","journal-title":"AIDS"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e0191389","DOI":"10.1371\/journal.pone.0191389","article-title":"Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age","volume":"13","author":"Snijdewind","year":"2018","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1097\/01.aids.0000253362.01696.9d","article-title":"Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth","volume":"20","author":"Szyld","year":"2006","journal-title":"AIDS"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1758-2652-14-42","article-title":"Birth outcomes in south African women receiving highly active antiretroviral therapy: a retrospective observational study","volume":"14","author":"van der Merwe","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/infdis\/jis728","article-title":"Combination antiretroviral use and preterm birth","volume":"207","author":"Watts","year":"2013","journal-title":"J Infect Dis"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","article-title":"Comparative safety of antiretroviral treatment regimens in pregnancy","volume":"171","author":"Zash","year":"2017","journal-title":"JAMA Pediatr"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e804","DOI":"10.1016\/S2214-109X(18)30218-3","article-title":"Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study","volume":"6","author":"Zash","year":"2018","journal-title":"Lancet Glob Health"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e25763","DOI":"10.1002\/jia2.25763","article-title":"Maternal weight and birth outcomes among women on antiretroviral treatment from conception in a birth surveillance study in Botswana","volume":"24","author":"Zash","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"101368","DOI":"10.1016\/j.eclinm.2022.101368","article-title":"Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: a systematic review and meta-analysis","volume":"46","author":"Cowdell","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/QAD.0000000000003432","article-title":"Perinatal outcomes associated with combination antiretroviral therapy compared with monotherapy","volume":"37","author":"Portwood","year":"2023","journal-title":"AIDS"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/QAD.0b013e32802ef2f6","article-title":"Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis","volume":"21","author":"Kourtis","year":"2007","journal-title":"AIDS"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12978-016-0149-5","article-title":"Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis","volume":"13","author":"Mesfin","year":"2016","journal-title":"Reprod Health"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e0198447","DOI":"10.1371\/journal.pone.0198447","article-title":"Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: systematic review and network meta-analysis including different study designs","volume":"13","author":"Veroniki","year":"2018","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0000000000001770","article-title":"Use of antiretroviral therapy during pregnancy and adverse birth outcomes among women living with HIV-1 in low- and middle-income countries: a systematic review","volume":"79","author":"Saleska","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref63","first-page":"38","article-title":"Safety and efficacy of lopinavir\/ritonavir during pregnancy: a systematic review","volume":"15","author":"Pasley","year":"2013","journal-title":"AIDS Rev"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"13326","DOI":"10.1111\/hiv.13326","article-title":"Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: systematic review and meta-analysis","volume":"6","author":"Sexton","year":"2022","journal-title":"HIV Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/AOG.0000000000002046","article-title":"Committee opinion no 700: methods for estimating the due date","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(14)60932-6","article-title":"International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the INTERGROWTH-21st project","volume":"384","author":"Villar","year":"2014","journal-title":"Lancet"},{"key":"ref67","volume-title":"The investigation and Management of the Small\u2013for\u2013Gestational\u2013age Fetus. Green-top Guideline No.31. London: Royal College of Obstetricians and Gynaecologists","year":"2014"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"00249","DOI":"10.1016\/S2352-3018(21)00249-6","article-title":"Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua","volume":"2","author":"Dunk","year":"2021","journal-title":"Lancet HIV"},{"key":"ref69","first-page":"91","article-title":"HIV, antiretroviral therapy, and hypertensive disorders in pregnancy: a systematic review and meta-analysis","volume-title":"J Acquir Immune Defic Syndr","author":"Browne","year":"1999"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"13265","DOI":"10.1038\/s41598-020-69966-0","article-title":"Innate lymphoid cells are reduced in pregnant HIV positive women and are associated with preterm birth","volume":"10","author":"Akoto","year":"2020","journal-title":"Sci Rep"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e13240","DOI":"10.1111\/aji.13240","article-title":"Changes in the V\u03b17.2+ CD161++ MAIT cell compartment in early pregnancy are associated with preterm birth in HIV-positive women","volume":"83","author":"Ravi","year":"2020","journal-title":"Am J Reprod Immunol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e0235162","DOI":"10.1371\/journal.pone.0235162","article-title":"\u03b3\u03b4 T cell frequencies are altered in HIV positive pregnant south African women and are associated with preterm birth","volume":"15","author":"Akoto","year":"2020","journal-title":"PLoS One"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1038\/s41598-021-89551-3","article-title":"Maternal HIV infection is associated with distinct systemic cytokine profiles throughout pregnancy in south African women","volume":"11","author":"Akoto","year":"2021","journal-title":"Sci Rep"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/infdis\/jiw004","article-title":"Low prolactin and high 20-alpha-hydroxysteroid dehydrogenase levels contribute to lower progesterone levels in HIV-infected pregnant women exposed to protease inhibitor-based combination antiretroviral therapy","volume":"213","author":"Papp","year":"2016","journal-title":"J Infect Dis"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/infdis\/jiu393","article-title":"HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction","volume":"211","author":"Papp","year":"2015","journal-title":"J Infect Dis"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1016\/S2352-3018(21)00150-8","article-title":"Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Price","year":"2021","journal-title":"Lancet HIV"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e25916","DOI":"10.1002\/jia2.25916","article-title":"Approaches to accelerating the study of new antiretrovirals in pregnancy","volume":"25","author":"Abrams","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2352-3018(21)00280-0","article-title":"Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap","volume":"9","author":"Joseph Davey","year":"2022","journal-title":"Lancet HIV"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"00687","DOI":"10.1016\/S1473-3099(22)00687-9","article-title":"Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women","volume":"11","author":"Eke","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2352-4642(22)00071-2","article-title":"Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis","volume":"6","author":"Wedderburn","year":"2022","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1323813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T04:51:06Z","timestamp":1709009466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1323813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":81,"alternative-id":["10.3389\/fmed.2024.1323813"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1323813","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"article-number":"1323813"}}